Thyroid Cancer

Perform thyroid ultrasound with a dedicated cervical lymph-node survey for every known or suspected thyroid nodule. The examination confirms the index lesion, identifies contralateral or multifocal nodules, and assesses cervical nodes that may alter the planned operation from thyroid surgery alone to compartment-directed nodal dissection. PubMedPubMedApproach to Thyroid Nodules: Diagnosis and Treatment - PMC

Use ultrasound-guided fine-needle aspiration (FNA) to establish malignancy when tissue diagnosis will change management. FNA is the most precise diagnostic test for thyroid nodules and has reduced unnecessary thyroid surgery; serum thyroglobulin should not be used to exclude malignancy because it lacks adequate diagnostic specificity and sensitivity in nodular thyroid disease. PubMedPubMedApproach to Thyroid Nodules: Diagnosis and Treatment - PMC

Treat rapid enlargement, dysphagia, neck pain, hoarseness, prior head or neck radiation, and a family history of thyroid cancer or polyposis syndromes as escalation features that warrant careful imaging review and tissue-directed planning rather than routine observation. PubMedPubMedApproach to Thyroid Nodules: Diagnosis and Treatment - PMC

When FNA or molecular testing indicates medullary thyroid carcinoma (MTC), do not apply the differentiated thyroid carcinoma (DTC) pathway. MTC arises from parafollicular cells, and molecular testing that strongly suggests MTC can appropriately change the preoperative plan toward total thyroidectomy with central and, when indicated by regional disease, lateral neck dissection. facsfacsUnexpected Diagnosis of Sporadic Medullary Thyroid Carcinoma | ACS

Offer thyroid lobectomy as a de-escalated surgical option for low-risk DTC that is smaller than 4 cm, confined to the thyroid, and without evidence of cervical nodal spread. This approach preserves contralateral thyroid tissue and avoids the added operative extent of total thyroidectomy in patients unlikely to benefit from routine radioactive iodine. thyroidthyroidVol 14 Issue 8 p.7-8 | American Thyroid Association

Use total thyroidectomy when disease extent or planned adjuvant management requires complete gland removal. In intermediate-risk patients with clinically apparent lateral neck metastasis (cN1b), NCCN guidance cited in contemporary surgical literature recommends total thyroidectomy; this is commonly paired with ipsilateral lateral neck dissection and, in usual practice, radioactive iodine. JAMA+1JAMALobectomy vs Total Thyroidectomy With Ipsilateral Lateral Neck Dissection for N1b Intermediate-Risk PapillaryJAMAThyroid Lobectomy and Neck Dissection for N1b Papillary Thyroid Carcinoma

Do not assume that cN1b status mandates the same operation in every patient. Propensity-matched observational cohorts of selected patients with primary tumors limited to one thyroid lobe and ipsilateral lateral neck metastases found no important difference in overall survival or recurrence between lobectomy plus ipsilateral lateral neck dissection and total thyroidectomy-based treatment; these data support multidisciplinary case selection rather than broad replacement of standard total-thyroidectomy pathways. JAMA+1JAMAThyroid Lobectomy and Neck Dissection for N1b Papillary Thyroid CarcinomaJAMALobectomy vs Total Thyroidectomy With Ipsilateral Lateral Neck Dissection for N1b Intermediate-Risk Papillary

Counsel explicitly about the tradeoff: total thyroidectomy facilitates radioactive iodine administration and thyroglobulin-centered surveillance but has been associated with higher complication rates, higher cost, and lower health-related quality-of-life outcomes than lobectomy in comparative literature. thyroidthyroidVol 15 Issue 5 p.9-10 | American Thyroid Association

In DTC, radioactive iodine is used after surgery to treat residual disease and may be curative in some metastatic cases, although metastatic radioiodine uptake is heterogeneous and cure is achieved in only a minority of patients with metastatic disease. NatureNatureTargeted therapies for thyroid tumors | Modern Pathology Use treatment planning and follow-up imaging in the context of postoperative risk and evidence of iodine-avid disease rather than treating radioiodine as a universal postoperative intervention. Nature+1NatureTargeted therapies for thyroid tumors | Modern PathologyWolters KluwerChapter 6: Risk Stratification and Surveillance in... : Journal of Head & Neck Physicians and Surgeons

Prescribe levothyroxine for risk-based TSH suppression in treated DTC and reassess the intensity as response-to-therapy category evolves. TSH can stimulate thyroid-cancer-cell growth through its receptor, while excessive long-term suppression has cardiovascular and skeletal tradeoffs; dynamic reassessment is therefore preferable to indefinite uniform suppression. Nature+2NatureTargeted therapies for thyroid tumors | Modern PathologyNatureCurrent advance of nanotechnology in diagnosis and treatment for malignant tumors | Signal Transduction and Targeted TherapyWolters KluwerChapter 6: Risk Stratification and Surveillance in... : Journal of Head & Neck Physicians and Surgeons

In patients receiving sorafenib for locally recurrent or metastatic progressive radioactive-iodine-refractory DTC, the FDA-labeled dose is 400 mg orally twice daily without food. Monitor TSH monthly and adjust thyroid replacement as needed: in the DECISION trial, TSH rose above 0.5 mU/L in 41% of sorafenib-treated patients versus 16% with placebo. accessdata fdaaccessdata fdaThis label may not be the latest approved by FDA. For current ...

Do not use radioactive iodine or TSH suppression as disease-directed therapy for MTC. For MTC, complete surgical removal offers the principal opportunity for cure, and neck-compartment management is determined by primary and regional disease rather than iodine avidity. Nature+1NatureTargeted therapies for thyroid tumors | Modern PathologythyroidVol 18 Issue 6 p.9-11 | American Thyroid Association

After treatment for DTC, measure serial thyroglobulin and thyroglobulin antibodies, maintain risk-based TSH suppression, and select radioactive iodine scanning or structural imaging according to dynamic risk stratification. A biochemical signal without localized disease and a structural lesion require different next steps; imaging escalation should be driven by the response category rather than a fixed uniform schedule. Wolters KluwerWolters KluwerChapter 6: Risk Stratification and Surveillance in... : Journal of Head & Neck Physicians and Surgeons

An excellent response permits de-intensification. Once an excellent response is achieved, initial low, intermediate, or high recurrence-risk estimates should be revised downward; reported disease-specific mortality is below 1% in this category, supporting less intensive suppression and investigation when there is no structural abnormality. Wolters KluwerWolters KluwerChapter 6: Risk Stratification and Surveillance in... : Journal of Head & Neck Physicians and Surgeons

Do not automatically intensify surveillance solely for biochemical incomplete response in low- to intermediate-initial-risk DTC. No deaths were reported among patients with biochemical incomplete response followed for up to 10 years in the cited surveillance review; intensify structural evaluation when a significant imaging abnormality is identified rather than treating every biochemical category as imminent structural progression. Wolters KluwerWolters KluwerChapter 6: Risk Stratification and Surveillance in... : Journal of Head & Neck Physicians and Surgeons

When recurrent or persistent structural disease is suspected, use neck ultrasound and, as indicated by prior radioactive-iodine uptake and response category, diagnostic or post-therapy whole-body scanning and cross-sectional imaging. Lack of uptake outside the thyroid bed on a post-treatment scan or absence of disease on recent radioiodine and neck imaging helps define the surveillance context but does not replace longitudinal biomarker trends. Wolters KluwerWolters KluwerChapter 6: Risk Stratification and Surveillance in... : Journal of Head & Neck Physicians and Surgeons